Barclays analyst Andrew Mok lowered the firm’s price target on Acadia Healthcare (ACHC) to $14 from $17 and keeps an Equal Weight rating on the shares. The company cut its guidance for the third time this year due to an unexpected $49M increase in legal expenses, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHC:
- Video: Marvell rises after earnings, Celestial AI deal
- Acadia Healthcare price target lowered to $19 from $22 at RBC Capital
- Acadia Healthcare price target lowered to $17 from $22 at Cantor Fitzgerald
- Acadia Healthcare price target lowered to $24 from $28 at UBS
- Leerink downgrades Acadia Healthcare on ‘real risk’ of legal liabilities